Dallas-based GeneIQ announced this week the appointment of Sami Shihabi as its new Chief Commercial Officer, according to a news release.
Shihabi will lead the commercial branch of the organization, encompassing responsibilities in sales, marketing, and revenue cycle management functions.
GeneIQ is a molecular diagnostics company specializing in Pharmacogenomic (PGx) and RT-PCR testing for infectious diseases, including COVID-19. Its Dallas lab services long-term care facilities, physician practices, governments and corporations.
“We are excited to have Sami join our leadership team at GeneIQ and are confident that he will be instrumental in helping us take great strides in the precision medicine space,” Frank Howard, CEO of GeneIQ, said in the release. “At our company, we emphasize the importance of the 3 P’s: people, product, process, and I’ve always felt strongly that people are the most important part of an organization.”
Shihabi brings over 25 years of health care experience to the role, having most recently led the Women’s Health Diagnostics and Gastroenterology Precision Medicine divisions at Progenity as Chief Commercial Officer.
Before Progenity, he served as CCO at Prometheus Laboratories and held various responsibilities at Bausch Health and Baxter Oncology.
“I am truly honored to join and complement the team at GeneIQ and work towards strengthening our presence in the marketplace while preparing for the next phase of growth,” Shihabi said in the release. “Patient wellness is at the core of our mission and will continue to drive our efforts to develop innovative genetic and pharmacogenetic testing products to help improve patient lives.”
